Kymera Short Sellers Step Back as KT-621 Bets Build

Kymera Therapeutics reports third-quarter results on October 29 with short sellers pulling back sharply even as the stock reaches its highest price in more than a year, a divergence that sharpens the question of whether the protein degradation platform can justify its $10.2 billion market cap.

Short interest has dropped nearly 9% over the past week to 12.7% of the free float, a move that ORTEX data shows is 3.3 standard deviations below the company's typical weekly change. That is a meaningful retreat, not just noise. The weekly decline of around 870,000 shorted shares is the fastest unwinding in at least a month, even as the position remains elevated in absolute terms at roughly 9.1 million shares. Borrowing costs are low at 0.56%, and availability is loose at 333%, meaning there are more than three shares available to lend for every share currently borrowed. The lending market offers no squeeze pressure here. Separately, two activists appear on Kymera's SEC 13D register: Baker Bros. Advisors LP, which disclosed a 10.9% stake (up from 9.5%) via Schedule 13D/A in December 2025, and BVF Partners, which filed a 13D/A in June 2026 at 6.3%, down from 8.5%. Stakes are as last disclosed around the 5% threshold, and a holder can fall below 5% without filing again.

The bull case centres on KT-621, Kymera's oral STAT6 degrader, which analysts believe could achieve biologic-like efficacy in a market where Dupixent has penetrated only around 10% of eligible patients. An accelerated phase 2b atopic dermatitis readout is targeted by year-end 2026, with phase 3 initiation pencilled in for mid-2027. Analyst sentiment has tilted firmly positive in recent months: Citigroup raised its target to $150, Stifel lifted to $152, and B of A Securities moved to $144, all maintaining Buy ratings. Raymond James initiated at Outperform with a $140 target in early October. The mean price target is $139.83 against a current price of $122.51, implying modest upside by Street consensus, though Guggenheim sits well above the pack at $170. Bears focus on execution risk: KT-485 trials in hidradenitis suppurativa and atopic dermatitis may face enrolment challenges, early data does not always survive into later stages, and pricing pressure in specialty indications adds an additional layer of risk for a company with no commercial revenue.

The stock has gained 8.8% over the past week, against a median of 0.8% for its closest peers. BCAX fell 45.5% on the week, while VERA and RCUS both declined. Kymera's outperformance is notable given that its short score of 70.5 ranks in the 11th percentile for short pressure, meaning the stock carries more short positioning than 89% of names in the universe even after recent covering. The analyst recommendation differential factor score is in the 92nd percentile, reflecting how decisively the Street has moved positive relative to peers. One index rebalance angle adds a mechanical layer: ORTEX puts the probability of Kymera graduating from the Russell 2000 to the Russell 1000 at 47% at the December 2026 semi-annual review, contingent on the stock holding above $118.52 at the October 30 rank date. If deleted from the Russell 2000, trackers would need to sell an estimated $998 million across 11.4 days of average volume.

Today's print will test whether Kymera's clinical milestones and cash runway, reported at $1.5 billion, are advancing on a schedule that justifies a position where even committed short sellers are stepping aside.